Neuphoria TherapeuticsNEUP +5.18%32 Market Cap is $24.48 Mil as of Jun. 27, 2026. GuruFocus rates NEUP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, Neuphoria Therapeutics ranks worse than 74.42% on this metric.
Neuphoria Therapeutics's quarterly market cap
declined
from Sep. 2025 ($27.80 Mil) to Dec. 2025 ($20.86 Mil) but then
increased
from Dec. 2025 ($20.86 Mil) to Mar. 2026 ($21.88 Mil).
Neuphoria Therapeutics's annual market cap
declined
from Jun. 2023 ($38,774.60 Mil) to Jun. 2024 ($1,828.95 Mil) and
declined
from Jun. 2024 ($1,828.95 Mil) to Jun. 2025 ($14.04 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Neuphoria Therapeutics's Enterprise Value for Today is $5.29 Mil.
Neuphoria Therapeutics (NAS:NEUP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neuphoria Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuphoria Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Neuphoria Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Neuphoria Therapeutics's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuphoria Therapeutics (NEUP) has a Market Cap of $24.48 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Neuphoria Therapeutics and its competitors. According to the industry distribution chart, Neuphoria Therapeutics ranks #1065 out of 1431 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Neuphoria Therapeutics' Market Cap too high?
Neuphoria Therapeutics' current Market Cap is $24.48 Mil. The Biotechnology industry median Market Cap is 113.83. Neuphoria Therapeutics' value of $24.48 Mil is 78.5% below this industry median. Based on the distribution chart, Neuphoria Therapeutics ranks #1065 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Neuphoria Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Market Cap compare to CRVO and IGC?
According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #1065 out of 1431 companies for Market Cap. This places Neuphoria Therapeutics in the lower half of its industry. The industry median Market Cap is 113.83. Neuphoria Therapeutics' value of $24.48 Mil is 78.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuphoria Therapeutics's current Market Cap of $24.48 Mil is 78.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Neuphoria Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuphoria Therapeutics's current Market Cap is $24.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Market Cap of $24.48 Mil. The current Market Cap is $24.48 Mil and 78.5% below the Biotechnology industry median of 113.83. Neuphoria Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Market Cap is $24.48 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
32GF Score
Get the complete analysis for NEUP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEUP has been successfully added to your 
